Effects of allopurinol and febuxostat on cardiovascular mortality in elderly heart failure patients
- 63 Downloads
Hyperuricemia is an emerging risk factor for the development of heart failure (HF) and is associated with a worsen prognosis of the disease. The effect of urate lowering drugs (ULT) and, in particular, the xanthine oxidase inhibitor in patients with HF is controversial. The aim of the study is to compare the effects of treatment with two different xanthine oxidase inhibitors (allopurinol or febuxostat) on cardiovascular mortality in elderly patients with chronic HF in a setting of clinical practice. In this observational trial, 255 elderly patients affected by chronic HF and treated with ULT on top of optimal medical treatment for HF. The sample included only outpatients with mild-to-moderate HF mainly secondary to chronic arterial hypertension or coronary artery disease and not previously hospitalized for HF. Patient treated with febuxostat (N. 120) and allopurinol (N. 135) were balanced for most of the baseline variables. In particular age, NYHA class distribution, drug treatment and renal function were comparable at the baseline and during the observation in both groups (p > 0.05). After a mean follow-up period of 5.1 years, the cumulative cardiovascular survival was 0.96 (95% CI 0.93–0.99) in febuxostat-treated patients and 0.89 (95% CI 0.84–0.93) in those treated with allopurinol. The between group difference, adjusted for the main confounding risk factors, was statistically significant (p = 0.04). Our study results suggest that possibility that febuxostat, a selective XO inhibitor, may favorably affect cardiovascular mortality in comparison with allopurinol in elderly patients with mild-to-moderate HF. This preliminary observation deserves further evaluation in the next future.
KeywordsAllopurinol Febuxostat Heart failure Hyperuricemia Mortality
This research was funded by institutional funding of the University of Bologna.
Compliance with ethical standards
Conflict of interest
Prof. Claudio Borghi is scientific consultant for Menarini International, no one of the other authors have direct nor indirect conflict of interest in the publication of this paper.
Statements of human and animal rights
The study was carried out in the setting of current clinical practice and has been carried out in agreement with the Declaration of Helsinki.
The study was approved by the local ethical board and each subject signed an informed consent.
- 2.Mantovani A, Targher G, Temporelli PL, Lucci D, Gonzini L, Nicolosi GL, Marchioli R, Tognoni G, Latini R, Cosmi F, Tavazzi L, Maggioni AP, Investigators GISSI-HF (2018) Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: a post hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial. Metabolism 83:205–215. https://doi.org/10.1016/j.metabol.2018.02.007 CrossRefGoogle Scholar
- 3.Hare JM, Mangal B, Brown J, Fisher C Jr, Freudenberger R, Colucci WS, Mann DL, Liu P, Givertz MM, Schwarz RP, Investigators OPT-CHF (2008) Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 51:2301–2309. https://doi.org/10.1016/j.jacc.2008.01.068 CrossRefGoogle Scholar
- 4.Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O’Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF, NHLBI Heart Failure Clinical Research Network (2015) Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation 131(20):1763–1771. https://doi.org/10.1161/circulationaha.114.014536 CrossRefGoogle Scholar
- 6.Cicero AF, Rosticci M, Fogacci F, Grandi E, D’Addato S, Borghi C, Brisighella Heart Study Group (2017) Serum uric acid level is associated to poorly controlled blood pressure and arterial stiffness in hypertensive subjects: data from the Brisighella Heart Study. Eur J Intern Med 37:38–42. https://doi.org/10.1016/j.ejim.2016.07.026 CrossRefGoogle Scholar
- 9.Nodera M, Suzuki H, Matsumoto Y, Kamioka M, Kaneshiro T, Yoshihisa A, Ohira T, Takeishi Y (2018) Association between serum uric acid level and ventricular tachyarrhythmia in heart failure patients with implantable cardioverter-defibrillator. Cardiology 140(1):47–51. https://doi.org/10.1159/000488851 CrossRefGoogle Scholar
- 10.Filippatos GS, Ahmed MI, Gladden JD, Mujib M, Aban IB, Love TE, Sanders PW, Pitt B, Anker SD, Ahmed A (2011) Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J 32:712–720. https://doi.org/10.1093/eurheartj/ehq473 CrossRefGoogle Scholar
- 11.Vaduganathan M, Greene SJ, Ambrosy AP, Mentz RJ, Subacius HP, Chioncel O, Maggioni AP, Swedberg K, Zannad F, Konstam MA, Senni M, Givertz MM, Butler J, Gheorghiade M, EVEREST trial investigators (2014) Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with Tolvaptan trial). Am J Cardiol 114(11):1713–1721. https://doi.org/10.1016/j.amjcard.2014.09.008 CrossRefGoogle Scholar
- 12.Otaki Y, Watanabe T, Kinoshita D, Yokoyama M, Takahashi T, Toshima T, Sugai T, Murase T, Nakamura T, Nishiyama S, Takahashi H, Arimoto T, Shishido T, Miyamoto T, Kubota I (2017) Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure. Int J Cardiol 228:151–157. https://doi.org/10.1016/j.ijcard.2016.11.077 CrossRefGoogle Scholar
- 16.Cicero AF, Morbini M, Urso R, Rosticci M, Parini A, Grandi E, D’Addato S, Borghi C, Brisighella Heart Study Group (2016) Association between self-reported snoring and arterial stiffness: data from the Brisighella Heart Study. Intern Emerg Med 11(1):77–83. https://doi.org/10.1007/s11739-015-1310-9 CrossRefGoogle Scholar
- 17.Cicero AF, Desideri G, Grossi G, Urso R, Rosticci M, D’Addato S, Borghi C, Brisighella Heart Study Group (2015) Serum uric acid and impaired cognitive function in a cohort of healthy young elderly: data from the Brisighella Study. Intern Emerg Med 10(1):25–31. https://doi.org/10.1007/s11739-014-1098-z CrossRefGoogle Scholar
- 18.Valente MA, Hillege HL, Navis G, Voors AA, Dunselman PH, van Veldhuisen DJ, Damman K (2014) The chronic kidney disease epidemiology collaboration equation outperforms the modification of diet in renal disease equation for estimating glomerular filtration rate in chronic systolic heart failure. Eur J Heart Fail 16(1):86–94. https://doi.org/10.1093/eurjhf/hft128 CrossRefGoogle Scholar
- 19.Cheitlin MD, Armstrong WF, Aurigemma GP, ACC, AHA, ASE et al (2003) ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (ACC/AHA/ASE committee to update the 1997 guidelines for the clinical application of echocardiography). J Am Soc Echocardiogr 16:1091–1110Google Scholar
- 20.Lang RM, Bierig M, Devereux RB et al (2005) Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463CrossRefGoogle Scholar
- 25.Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R, Kohler C, Harrison DG, Hornig B, Drexler H (2002) Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 106:3073–3078CrossRefGoogle Scholar
- 28.Cicero AF, Kuwabara M, Johnson R, Bove M, Fogacci F, Rosticci M, Giovannini M, D’Addato S, Borghi C, Brisighella Heart Study group (2018) LDL-oxidation, serum uric acid, kidney function and pulse-wave velocity: data from the Brisighella Heart Study cohort. Int J Cardiol 261:204–208. https://doi.org/10.1016/j.ijcard.2018.03.077 CrossRefGoogle Scholar
- 30.Foody J, Turpin RS, Tidwell BA, Lawrence D, Schulman KL (2017) Major cardiovascular events in patients with gout and associated cardiovascular disease or heart failure and chronic kidney disease initiating a xanthine oxidase inhibitor. Am Health Drug Benefits 10:393–401Google Scholar
- 32.Molino-Lova R, Sofi F, Pasquini G, Vannetti F, Del Ry S, Vassalle C, Clerici M, Sorbi S, Macchi C (2017) Higher uric acid serum levels are associated with better muscle function in the oldest old: results from the Mugello Study. Eur J Intern Med 41:39–43. https://doi.org/10.1016/j.ejim.2017.03.014 CrossRefGoogle Scholar
- 33.Desideri G, Castaldo G, Lombardi A, Mussap M, Testa A, Pontremoli R, Punzi L, Borghi C (2014) Is it time to revise the normal range of serum uric acid levels? Eur Rev Med Pharmacol Sci. 18(9):1295–1306Google Scholar
- 34.Bredemeier M, Lopes LM, Eisenreich MA, Hickmann S, Bongiorno GK, d’Avila R, Morsch ALB, da Silva SF, Campos GGD (2018) Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 18(1):24. https://doi.org/10.1186/s12872-018-0757-9 CrossRefGoogle Scholar
- 35.Borghi C, Cicero AF (2017) Uric acid: beyond the interpretation of serum levels. Brit Med J 357:j2376Google Scholar